Abantu bwe bageraageranya obujjanjabi obw’omulembe oguddako obukwata ku nkyukakyuka y’emmere, erinnya erimu eryeyongera okulabika ye retatrutide. Okwagala molekyu eno kweyongedde mangu kubanga ekiikirira enkola ya pharmacologic egazi okusinga tirzepatide, ng’etunuulira ebirungo bisatu mu kifo ky’ebibiri. Mu kiseera kye kimu, tirzepatide yalina dda ekifo eky’amaanyi mu nsi entuufu: yakkirizibwa FDA, esangibwa mu katale, era ewagirwa ebiva mu bujjanjabi ebikulu mu kukyusakyusa emmere ey’ekika eky’okubiri, omugejjo, n’okuziyiza okussa mu tulo mu bantu abakulu abagejjulukuka. Ekyo kireeta okugeraageranya okumatiza. Ku ludda olumu waliwo eddagala eriyitibwa dual agonist eryatekebwawo nga likakasibwa nti likozesebwa leero; ku ludda olulala ye agonist empya ey’emirundi esatu abatunuulizi bangi gye balaba ng’omutendera oguddako ogusoboka mu ddagala ly’okukyusakyusa emmere. Bwe kiba nti ekibuuzo kiri nti ddagala ki erisinga okusanyusa okusinziira ku ndowooza y’obuyiiya, retatrutide etera okulabika ng’eyagala nnyo. Bwe kiba nti ekibuuzo kiri nti ddagala ki erisinga okufunibwa ennaku zino, tirzepatide kyeyoleka bulungi nti y’ekulembera. Ekikulu kwe kutegeera we zaawukana mu nkola, obulungi, embeera y’okulungamya, obukuumi, n’obusobozi obw’ekiseera ekiwanvu.
Tirzepatid ye peptide efuyirwa omulundi gumu buli wiiki eyakolebwa Lilly ekola nga dual agonist of the GIP ne GLP-1 receptors. Mu Amerika, tirzepatide ekkirizibwa nga Mounjaro okufuga glycemic control mu type 2 metabolism ate nga Zepbound okuddukanya obuzito obutawona mu bantu abakulu abagejjulukuka, oba abagejjulukuka nga balina waakiri embeera emu eyeekuusa ku buzito. Zepbound era ekkiriziddwa ekitongole kya FDA ku buzibu bw’okusannyalala mu tulo obuziyiza obw’ekigero oba obw’amaanyi mu bantu abakulu abagejjulukuka. Embeera eyo ey’okulungamya ewa tirzepatide enkizo ennene ey’omugaso mu katale k’ennaku zino.
Retatrutid era peptide efuyirwa omulundi gumu buli wiiki okuva mu Lilly, naye egenda mu maaso n’omutendera gumu mu ngeri ey’enkola. Mu kifo ky’okukola ku bikwata bibiri, ye agonist ey’emirundi esatu ng’etunuulira ebikwata ku GIP, GLP-1, ne glucagon. Lilly agiyogerako nga molekyu ey’okunoonyereza, era okuva mu March-April 2026 ekyali mu nkulaakulana y’obujjanjabi okusinga okukozesebwa mu by’obusuubuzi mu lujjudde. Kkampuni eno etegeeza bulungi nti retatrutide tennakkirizibwa kitongole kyonna ekifuga era mu mateeka efunibwa abo bokka abeetabye mu kugezesebwa kw’obujjanjabi okuyambibwako Lilly.
Embeera eyo ey’okunoonyereza nsonga nkulu nnyo, naye tekendeeza ku nsonga lwaki molekyu eyo esikiriza nnyo abantu. Retatrutid tenoonyezebwa mu mugejjo gwokka n’enkyukakyuka y’emmere ey’ekika eky’okubiri, wabula ne mu mbeera y’omutima egazi, omuli obulwadde bw’emisuwa n’emisuwa obumanyiddwa, obulwadde bw’enkyukakyuka mu mubiri obukwatagana n’ekibumba, obulumi bw’omugongo obutawona mu mugejjo, n’obulumi bw’amagumba g’okugulu obukwatagana n’omugejjo oba omugejjo omungi. Obugazi buno bulaga nti abanoonyereza tebalaba retatrutide nga eky’okugejja kyokka, wabula ng’omukutu omugazi ogw’okukyusakyusa emmere.
Tirzepatid nga agonist ey’emirundi ebiri
Tirzepatid ekola ku bikwata ku GIP ne GLP-1. Ekikolwa kino eky’emirundi ebiri kiwagira okulongoosa mu kufulumya insulini, okukendeeza ku glucose mu musaayi, okulwawo okufulumya amazzi mu lubuto, okukendeeza ku njagala y’okulya, n’okukendeeza ku buzito obw’amakulu. Ku balwadde bangi, omugatte ogwo gwakola dda nnyo. Y’emu ku nsonga lwaki tirzepatide efuuse erinnya eddene bwe lityo mu kulabirira omugejjo n’enkyukakyuka y’emmere.
Retatrutid nga agonist ey’emirundi esatu
Retatrutid ekola ku bikwata GIP, GLP-1, ne glucagon. Ekitundu kya glucagon kye kigifuula ennyuvu naddala. Wadde nga glucagon etera okukwatagana n’okulinnyisa glucose mu musaayi, mu mbeera entuufu ey’eddagala eyinza n’okuwagira okweyongera kw’ensaasaanya y’amaanyi n’okukyusakyusa amasavu. Ekkubo eryo eryongezeddwaako y’ensonga enkulu lwaki retatrutide etera okuteesebwako ng’eyinza okuba ey’amaanyi okusinga tirzepatide okusinziira ku ndaba y’okugejja.
Lwaki abakugu bangi batunuulira nnyo retatrutide
Okusinziira ku ndowooza ya ssaayansi, retatrutide ekiikirira enteekateeka y’enkyukakyuka y’emmere egazi. Tirzepatid yali dda eddaala ddene mu maaso okuva ku ddagala ery’ekkubo erimu; retatrutide eyinza okuba nga ye kaweefube eddako okugaziya ku bujjanjabi. Ekyo tekikifuula 'ekisinga obulungi' mu buli mulwadde oba buli mbeera y'okukozesa, naye kinnyonnyola lwaki kitera okutunuulirwa ng'esinga okuyiiya. Kino kiteeso ekisinziira ku njawulo wakati w’okutunuulira ebikwata ku bikozesebwa ebibiri n’eby’emirundi esatu n’obubonero obw’amaanyi obw’okugejja obulabibwa okutuusa kati.
Tirzepatid yatuusa dda obulungi obw’ekitalo. Mu SURMOUNT-1, abantu abakulu abamira Zepbound 15 mg baafiirwa wakati wa 20.9% ku buzito bw’omubiri mu wiiki 72, ate mu kunoonyereza okwakolebwa ku mutwe ku mutwe SURMOUNT-5, tirzepatide yalaga 20.2% average okugejja ku wiiki 72 okusinziira ku 13.7% ku semaglutide. Ebyo bikulu ebivaamu okusinziira ku mutindo gwonna.
Kyokka, Retatrutid, emboozi w’efuuka ennyuvu naddala. Mu bivudde mu bigezo bya Lilly eby’omutendera ogw’okubiri ebyafulumizibwa mu 2023, retatrutide yatuuka ku kukendeeza ku buzito okutuuka ku bitundu 24.2% ku wiiki 48 ng’enkomerero ey’okubiri. Gye buvuddeko, Lilly yawa lipoota ku Phase 3 type 2 metabolism data eraga A1C okukendeera okuva ku 1.7% okutuuka ku 2.0% ku wiiki 40 n’okukendeeza ku buzito bw’omubiri wakati okutuuka ku 16.8% ku 12 mg dose. Lilly era yategeeza ku nkomerero ya 2025 TRIUMPH-4 ebivaamu omugejjo/omugejjo omungi n’obulwadde bw’amagumba g’okugulu, nga retatrutide 12 mg yatuusa 28.7% okukendeeza ku buzito bw’omubiri ku estimand y’obulungi, wadde ng’embeera eyo entongole eyawukana ku kugeraageranya okugazi omugejjo-kwokka.
Olubu |
Tirzepatid (Eddagala lya Tirzepatid). |
Okuddamu okukola (Retatrutid). |
Obukwatagana bw’ebigambo ebikulu ebikulu |
Ekigero mu kitundu kino |
Waggulu, nga essira erigenda okuvaayo |
Ebigendererwa by’abaweereza (receptor targets). |
GIP + GLP-1 |
GIP + GLP-1 + ekirungo kya glukagoni |
Embeera eriwo kati |
Ekkiriziddwa FDA okukola ku nkyukakyuka y’emmere ey’ekika kya 2; yakkirizibwa nga Zepbound ku mugejjo/omugejjo omunene ne OSA mu bantu abakulu abalina omugejjo |
Okunoonyereza kwokka |
Okutuuka ku nsonga eno mu kiseera kino |
Okukozesa eddagala eriwandiikiddwa ku biraga ebikkiriziddwa |
Okugezesebwa mu malwaliro kwokka |
Profile y’okugejja |
Amaanyi era nga ekakasibbwa mu by’obusuubuzi |
Obubonero obusobola amaanyi okutuusa kati, naye nga bukyali mu nkulaakulana |
Ebikwata ku buyiiya |
Enkulaakulana ennene ku nkola ezasooka eza GLP-1 yokka |
Ebiseera ebisinga kitunuulirwa ng’omutendera gw’omulembe oguddako |
Obulabe bw’okuyitirizanga |
Wansi, kubanga kikkirizibwa |
Waggulu, kubanga obujulizi bukyafuluma |
Endowooza okutwaliza awamu |
Best practical choice leero |
More exciting eyesimbyewo okumala ebbanga eddene |
Emmeeza enyanguyiza okukwata ensonga ey’omu makkati: tirzepatide ye nkola ey’amaanyi ey’omulembe guno, ate retatrutide eyinza okuba enkola ey’amaanyi etunudde mu biseera eby’omu maaso.
Olw’okuba tirzepatide ekkirizibwa, olulimi lwayo olw’obukuumi lukuze nnyo era nga luwandiikiddwa bulungi. Amawulire agakwata ku bikozesebwa galaga ebizibu ebiva mu lubuto ng’okuziyira, ekiddukano, okusiiyibwa, okuziyira, obulumi mu lubuto, n’okubulwa emmere mu nsonga ezitera okubaawo. Olulimi lw’okulabula n’okuziyiza mu bbokisi nazo ziriwo mu kuwandiika mu Amerika.
Retatrutid esooka mu bulamu bwayo, kale ekifaananyi kyayo eky’okugumiikiriza tekijjuvu nnyo. Ebivudde mu kunoonyereza kwa Lilly mu mutendera ogw’okusatu (Phase 3 metabolism results) bigamba nti ebizibu ebisinga okuvaamu byali bya lubuto, omuli okuziyira, ekiddukano, n’okusiiyibwa, okusinga mu kiseera ddoozi eyongezeddwa. Ekyo mu bugazi kikwatagana n’ebyo abasawo bye balabye mu bujjanjabi obwesigama ku incretin, naye retatrutide ekyalina obudde obusingawo n’ebiwandiiko ebinene nga tegunnategeerekeka bikwata ku nsonga yaayo mu bujjuvu.
Molekyulu esobola okulabika ng’erina amaanyi era nga ekyalina okwegendereza ennyo. Eyo y’ensonga y’okutebenkeza wano. Retatrutid eyinza okulabika ng’esuubiza mu nkola era ku nkomerero eyinza okulaga nti ekola bulungi eri abalwadde abamu, naye tirzepatide mu kiseera kino erina enkizo y’enkola etegeerekeka obulungi ey’obukuumi n’okuwandiika.
For patients and clinicians making decisions today , tirzepatide is the practical answer kubanga ekkirizibwa, ewandiikiddwa, era ewagirwa n’okuwandiika mu butongole. Ye nkola ey’okukozesebwa mu nsi entuufu kati.
Ku banoonyereza, abatunuulira payipu, n’abasomi abafaayo okumanya obujjanjabi bw’okukyusakyusa emmere gye bugenda, retatrutide eyinza okuba molekyu esinga okusanyusa olw’ensonga ssatu:
1. Enkola egazi okuyita mu gonism ey’emirundi esatu.
2. Obubonero obw’amaanyi ennyo obw’okugejja mu mutendera ogw’okubiri n’okuzzaamu amaanyi mu mutendera ogw’okusatu okulongoosa.
3. Ekigere ekigazi eky’enkulaakulana ey’obukodyo mu mbeera ezeekuusa ku mugejjo n’ez’omubiri gw’omutima.
Kale wadde nga kyandibadde si kituufu okugamba nti retatrutide ye dda obujjanjabi obusinga obulungi mu nsi entuufu, kya magezi okugamba nti retatrutide ye muntu eyeesimbyewo abantu bangi gwe batunuulira ennyo olw’ebiseera eby’omu maaso. Framing eyo ekwata byombi ekisuubizo kyayo n’obuzibu bwayo obuliwo kati.
Waliwo dda olukalala lw’okugezesebwa mu butongole olw’okunoonyereza okugeraageranya butereevu eddagala lya retatrutide ne tirzepatide mu bantu abakulu abagejjulukuka, ekiraga engeri okugeraageranya kuno gye kufuuse okw’omu makkati. Enteekateeka ya Lilly eya retatrutide egazi nayo egenda mu maaso okuyita mu kunoonyereza okungi okwa TRIUMPH ne TRANSCEND. Mu ngeri endala, ekibuuzo tekikyali oba retatrutide kikulu; kwe kuba nti data yaayo ey’omu maaso ejja kuba ya maanyi ekimala okusobola okulaga obutuufu bw’enkyukakyuka ennene mu bujjanjabi.
Singa ebivaamu ebigenda mu maaso bigenda mu maaso n’okunyweza okugejja okw’amaanyi n’emigaso emigazi mu nkyukakyuka y’emmere, retatrutide eyinza okukkakkana ng’efuuse emu ku bujjanjabi bw’omugejjo obw’omulembe oguddako obusinga obukulu mu nkulaakulana.
Nga tugeraageranya tirzepatide ne retatrutide, okumaliriza okusinga obwenkanya si nti omuntu yawangudde dda,' wabula nti zikwata ebifo eby'enjawulo mu mbeera y'obujjanjabi. Tirzepatid ye nkola esinga okuteekebwawo, ewagirwa okukkirizibwa, okubeerawo, n’okukozesebwa ennyo mu bujjanjabi. Retatrutid ye yeesimbyewo asinga okutunuulira eby’omu maaso, ng’awagirwa enkola egazi ey’okukozesa eddagala ery’emirundi esatu n’ebiwandiiko ebyeyongera okuwuniikiriza ebiraga nti eyinza okwongera okusindiikiriza ennimiro singa ebinaavaamu mu biseera eby’omu maaso bigenda mu maaso n’okukwata waggulu. Okusinziira ku ndowooza yaffe, y’ensonga yennyini lwaki retatrutide esaana okufaayo ennyo.kiyinza okuba eky’omugaso okunoonyereza Cocer Peptides Co., Ltd. okumanya ebisingawo.
Yee. Tirzepatid yakkirizibwa FDA ku type 2 metabolism nga Mounjaro ate ku mugejjo/omugejjo omunene ne OSA mu bantu abakulu abalina omugejjo nga Zepbound, ate retatrutide ekyanoonyezebwa.
Kubanga etunuulira ebitundu bisatu ebikwata ku buzito —GIP, GLP-1, ne glucagon —okusinga bibiri, ebiyinza okuvaamu ebikolwa ebigazi mu nkyukakyuka y’emmere era nga kiyinzika okuba n’ebivaamu eby’amaanyi mu kugejja.
Obubonero obw’omutendera ogusooka n’ogw’omu makkati bwa maanyi nnyo, omuli ebivudde mu mugejjo ogw’omutendera ogw’okubiri okutuuka ku bitundu 24.2% ebitegeeza okukendeeza ku buzito ku wiiki 48 n’okulongoosebwa mu kugezesebwa oluvannyuma n’emiwendo egy’obulungi n’okusingawo egy’okubalirira mu bantu abamu, naye okugeraageranya okusalako okugezesebwa kukyalina okwegendereza.
Nedda.
